Patents by Inventor Wolfgang MIKULITS

Wolfgang MIKULITS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Soluble AXL receptor tyrosine kinase in the diagnosis of cancer
    Patent number: 10823737
    Abstract: The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.
    Type: Grant
    Filed: March 18, 2015
    Date of Patent: November 3, 2020
    Assignee: Medizinische Universität Wien
    Inventors: Wolfgang Mikulits, Patrick Reichl
  • SOLUBLE AXL RECEPTOR TYROSINE KINASE IN THE DIAGNOSIS OF CANCER
    Publication number: 20170146540
    Abstract: The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.
    Type: Application
    Filed: March 18, 2015
    Publication date: May 25, 2017
    Applicant: Medizinische Universität Wien
    Inventors: Wolfgang MIKULITS, Patrick REICHL
  • 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS
    Publication number: 20150368248
    Abstract: This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines.
    Type: Application
    Filed: February 5, 2014
    Publication date: December 24, 2015
    Applicants: BIOPATTERNS S.R.O., UNIVERZITA PALACKEHO V OLOMOUCI
    Inventors: Tomas GUCKY, Radek JORDA, Marek ZATLOUKAL, Vladimir KRYSTOF, Lucie RAROVA, Eva REZNICKOVA, Wolfgang MIKULITS, Miroslav STRNAD